ESTRO 2024 - Abstract Book

S292

Brachytherapy - Head & neck, skin, eye

ESTRO 2024

Purpose/Objective:

Kaposi sarcoma (KS) is a multi-focal, angioproliferative neoplasm that usually appears on the skin, but can also involve the visceral organs. Since KS lesions are considered very radiosensitive, the most widely advocated type of treatment, with excellent local control is radiotherapy based. HDR brachytherapy is considered superior to EBRT in terms of dosimetric coverage that is related to lower complication rates. In order to choose between these two techniques, characteristics of the patient, Karfnosky performance status (KPS), and patient’s delivery comfort would be considered.

Material/Methods:

Between June 2010 and February 2023, we treated 11 patients for a total of 39 lesions patients with KS with HDR IRT. Patients underwent brachytherapy treatment for a total dose ranging from 10 to 30 Gy (10 Gy per fraction). Toxicities were recorded using the Common Terminology Criteria for Adverse Events scale (CTCAE) v. 4.03. Median follow up was 41.1 months.

Results:

Median age was 61,8 years. Acute toxicity was recorded in 22 lesion treated (53.8%). Grade 1 erythema appeared in 15 cases with late persistence in 5 cases, despite the application of eudermic cream in all cases;Grade 2 erythema appeared in 5 cases, with regression to grade 1 in two cases and progression to superintensive ulcer from Pseudomonas Aeruginosa in one case, treated by specialist. Towards the end of each treatment schedule, epidermolysis developed which was resolved within 3 weeks; Grade 3 skin toxicity apperars in 1 case (2.6%) and was managed with dressings and close outpatient follow-up until grade 1 toxicity. At last follow-up, 64.1% (25/39 lesions) patients were disease free and 35.9% (14/39) recorded a partial response.

Conclusion: